SAN FRANCISCO -- In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) recurrence, according to a randomized study reported here.

The researchers found that after 3 years of follow-up, time to recurrence was lower for participants assigned to aspirin versus placebo. A similar trend was seen for disease-free survival hazard ...

The National Cancer Institute predicts that colorectal cancers will make up 8% of new cancer cases in 2025, and it is often recurring, so scientists are looking for ways to reduce the risk of it ...

Among patients who had undergone curative surgery for primary colorectal cancer, the screening methods of computed tomography and carcinoembryonic antigen each provided an improved rate of surgical ...

Low-dose aspirin reduced colorectal cancer (CRC) recurrence rates by more than half in patients with tumors harboring mutations in the PI3K signaling pathway, according to findings from the phase 3 ...

Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...

Singapore, 17 March 2025 – A large-scale, international, multicentre, phase 3 clinical trial of aspirin for the secondary prevention of colorectal cancer has concluded. Led by Singapore ...

Colon and rectal cancer disproportionately impact the Black community. A new study published in the Journal of Clinical Oncology suggests that a common over-the-counter drug may significantly reduce ...

A retrospective study of patients with distal rectal cancer at Memorial Sloan Kettering Cancer Center (MSK) has found a higher rate of local recurrence after intersphincteric resection with handsewn ...

Berberine significantly reduced adenoma recurrence and colorectal neoplasm occurrence in a 6-year follow-up study of nearly 800 patients post-polypectomy. The study found that berberine's ...

A recent study published in Engineering has shed light on a novel therapeutic target for improving anti-angiogenic treatment in colorectal cancer (CRC).